Genprex Inc
GNPX1.860USD
-0.030-1.59%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
1.87MMarket Cap
0.03P/E TTM
More Details of Genprex Inc Company
Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The Company's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. Its oncology drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is developed in combination with approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). GPX-002 is being developed by the Company using the same construct for the treatment of both Type 1 diabetes and Type 2 diabetes. GPX-002 for Type 1 diabetes is designed to work by transforming alpha cells in the pancreas into functional beta-like cells.
Genprex Inc Info
Ticker SymbolGNPX
Company nameGenprex Inc
IPO dateMar 29, 2018
CEOConfer (Ryan M)
Number of employees15
Security typeOrdinary Share
Fiscal year-endMar 29
Address3300 Bee Cave Road, Suite 650-227
CityAUSTIN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code78746
Phone18777744679
Websitehttps://www.genprex.com/
Ticker SymbolGNPX
IPO dateMar 29, 2018
CEOConfer (Ryan M)
Company Executives of Genprex Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Mark Stanley Berger, M.D.
Dr. Mark Stanley Berger, M.D.
Chief Medical Officer
Chief Medical Officer
359.00
+327.38%
Mr. Brent M. Longnecker
Mr. Brent M. Longnecker
Independent Director
Independent Director
174.00
+120.25%
Mr. William R. (Will) Wilson, Jr.
Mr. William R. (Will) Wilson, Jr.
Independent Director
Independent Director
--
--
Mr. Jose Antonio Moreno Toscano
Mr. Jose Antonio Moreno Toscano
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Ryan M. Confer
Mr. Ryan M. Confer
President, Chief Executive Officer, Chief Financial Officer, Director
President, Chief Executive Officer, Chief Financial Officer, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Mark Stanley Berger, M.D.
Dr. Mark Stanley Berger, M.D.
Chief Medical Officer
Chief Medical Officer
359.00
+327.38%
Mr. Brent M. Longnecker
Mr. Brent M. Longnecker
Independent Director
Independent Director
174.00
+120.25%
Mr. William R. (Will) Wilson, Jr.
Mr. William R. (Will) Wilson, Jr.
Independent Director
Independent Director
--
--
Mr. Jose Antonio Moreno Toscano
Mr. Jose Antonio Moreno Toscano
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Ryan M. Confer
Mr. Ryan M. Confer
President, Chief Executive Officer, Chief Financial Officer, Director
President, Chief Executive Officer, Chief Financial Officer, Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Intracoastal Capital, L.L.C.
0.73%
The Vanguard Group, Inc.
0.37%
Susquehanna International Group, LLP
0.29%
Jane Street Capital, L.L.C.
0.18%
Geode Capital Management, L.L.C.
0.14%
Other
98.28%
Shareholders
Shareholders
Proportion
Intracoastal Capital, L.L.C.
0.73%
The Vanguard Group, Inc.
0.37%
Susquehanna International Group, LLP
0.29%
Jane Street Capital, L.L.C.
0.18%
Geode Capital Management, L.L.C.
0.14%
Other
98.28%
Shareholder Types
Shareholders
Proportion
Investment Advisor
0.92%
Corporation
0.74%
Research Firm
0.19%
Investment Advisor/Hedge Fund
0.16%
Individual Investor
0.09%
Other
97.91%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
74
23.81K
1.46%
+9.38K
2025Q2
81
575.80K
1.72%
-243.74K
2025Q1
89
477.10K
1.64%
-339.91K
2024Q4
95
389.70K
4.58%
-292.57K
2024Q3
94
258.58K
9.54%
-122.06K
2024Q2
94
310.88K
14.00%
+53.87K
2024Q1
96
169.16K
8.97%
-35.44K
2023Q4
102
157.12K
10.36%
-117.81K
2023Q3
108
205.91K
13.93%
-106.85K
2023Q2
120
136.56K
10.18%
-102.21K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
15.31K
0.04%
--
--
Jun 30, 2025
Susquehanna International Group, LLP
304.39K
0.71%
+304.39K
--
Jun 30, 2025
Geode Capital Management, L.L.C.
75.20K
0.18%
-8.49K
-10.15%
Jun 30, 2025
UBS Financial Services, Inc.
131.00K
0.31%
+88.56K
+208.67%
Jun 30, 2025
Schiketanz Capital Advisors GmbH
76.50K
0.18%
--
--
Apr 30, 2025
Confer (Ryan M.)
32.97K
0.08%
+23.60K
+251.92%
Jun 30, 2025
Varner (John Rodney)
25.23K
0.06%
--
--
Jun 30, 2025
Berger (Mark Stanley)
17.97K
0.04%
+13.75K
+325.75%
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Oct 17, 2025
Merger
50→1
Jan 31, 2024
Merger
40→1
Jan 31, 2024
Merger
40→1
Jan 31, 2024
Merger
40→1
Jan 31, 2024
Merger
40→1
Date
Type
Ratio
Oct 17, 2025
Merger
50→1
Jan 31, 2024
Merger
40→1
Jan 31, 2024
Merger
40→1
Jan 31, 2024
Merger
40→1
Jan 31, 2024
Merger
40→1
FAQs
Who are the top five shareholders of Genprex Inc?
The top five shareholders of Genprex Inc are:
The Vanguard Group, Inc. holds 15.31K shares, accounting for 0.04% of the total shares.
Susquehanna International Group, LLP holds 304.39K shares, accounting for 0.71% of the total shares.
Geode Capital Management, L.L.C. holds 75.20K shares, accounting for 0.18% of the total shares.
UBS Financial Services, Inc. holds 131.00K shares, accounting for 0.31% of the total shares.
Schiketanz Capital Advisors GmbH holds 76.50K shares, accounting for 0.18% of the total shares.
The Vanguard Group, Inc. holds 15.31K shares, accounting for 0.04% of the total shares.
Susquehanna International Group, LLP holds 304.39K shares, accounting for 0.71% of the total shares.
Geode Capital Management, L.L.C. holds 75.20K shares, accounting for 0.18% of the total shares.
UBS Financial Services, Inc. holds 131.00K shares, accounting for 0.31% of the total shares.
Schiketanz Capital Advisors GmbH holds 76.50K shares, accounting for 0.18% of the total shares.
What are the top three shareholder types of Genprex Inc?
The top three shareholder types of Genprex Inc are:
Intracoastal Capital, L.L.C.
The Vanguard Group, Inc.
Susquehanna International Group, LLP
Intracoastal Capital, L.L.C.
The Vanguard Group, Inc.
Susquehanna International Group, LLP
How many institutions hold shares of Genprex Inc (GNPX)?
As of 2025Q3, 74 institutions hold shares of Genprex Inc, with a combined market value of approximately 23.81K, accounting for 1.46% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -0.26%.
What is the biggest source of revenue for Genprex Inc?
In --, the -- business generated the highest revenue for Genprex Inc, amounting to -- and accounting for --% of total revenue.
